



## Surmodics IVD Launches Breakthrough MatrixGuard™ Diluent

July 31, 2018

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 31, 2018-- Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for *in vitro* diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of MatrixGuard™ Diluent. *MatrixGuard Diluent* provides assay developers unsurpassed blocking whereby matrix interferences are effectively blocked while the intended assay signal is maintained.

Unlike other diluents that either are marginally effective at blocking matrix interferences or alternatively block out true assay signal, *MatrixGuard Diluent* achieves the goal of maximum blockade of matrix interferences while simultaneously allowing the intended signal to be maintained. *MatrixGuard Diluent* significantly reduces the risk of false positives and has excellent three-year stability. Along with all Surmodics reagents, *MatrixGuard Diluent* is manufactured in Surmodics' ISO 13485 and 9001 certified facility to ensure quality and lot-to-lot consistency.

With the launch of *MatrixGuard Diluent*, we continue our commitment to be a premier provider of assay components to improve performance and manufacturability of immunoassays," said Joe Stich, Vice President and General Manager of Surmodics IVD, the company's In Vitro Diagnostic business. "The Surmodics IVD team has truly developed a new gold standard diluent for assay developers that consistently balances outstanding blocking activity of matrix interferences while maintaining assay signal across multiple assay formats."

Surmodics IVD products immediately improve assay performance and manufacturability of assays by lowering backgrounds, increasing signal generation and providing longer shelf lives for immunoassay production. The addition of *MatrixGuard Diluent* augments the company's leading portfolio of products, including:

- The Immunoassay Stabilizer family preserves the conformation and activity of dried proteins coated on a wide range of surfaces, keeping antibodies and antigens at peak performance for long durations. At the same time, the blocking mechanisms in these reagents reduce non-specific binding of interfering proteins to maximize assay sensitivity.
- The StabilZyme® family provides unparalleled long-term stability of protein conjugates at working strength concentrations. Surmodics formulations for HRP conjugates, AP conjugates and general protein applications ensure that assay developers have a complete set of tools to address the labile nature of each protein of interest.
- BioFX® TMB substrate family outperforms competitors for low background, stability and sensitivity with a variety of kinetic rate substrates. The one-component formulations provide optimal signal generation and longer shelf lives.

### About Surmodics, Inc.

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for *in vitro* diagnostic (IVD) immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address unmet clinical needs for its medical device customers and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface technologies, along with enhanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease.

Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit our IVD website at [www.surmodics.com/ivd](http://www.surmodics.com/ivd). The content of Surmodics' website is not part of this press release or part of any filings that the company makes with the SEC.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180731005233/en/>

Source: Surmodics, Inc.

### Surmodics, Inc.

Tim Arens, 952-500-7000

[ir@surmodics.com](mailto:ir@surmodics.com)